20 completed, 2 active not recruiting, 2 terminated, 2 withdrawn. 28 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 20, Active not recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 6 | Completed 5, Unknown 1 |
Follow Eosinophilic Esophagitis: new trials by email Literature Review of Eosinophilic Esophagitis trials Research Report on Eosinophilic Esophagitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis dupilumab - Eosinophilic Esophagitis (EoE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 20 | 2025-11-10 | 2026-09-29 |
| 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 218 | 2022-12-29 | 2025-08-13 |
| Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Tezepelumab, Placebo - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | AstraZeneca | 368 | 2022-11-10 | 2026-10-30 |
| Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538 - Eosinophilic Esophagitis | Phase 3 | Completed | Celgene | 367 | 2022-08-09 | 2026-04-06 |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial APT-1011, Placebo oral tablet - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 6 | 2021-09-30 | 2023-09-21 |
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE Budesonide - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | Dr. Falk Pharma GmbH | 308 | 2021-05-21 | 2026-08-28 |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Completed | Allakos Inc. | 94 | 2021-05-20 | 2024-01-02 |
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538, Placebo - Eosinophilic Esophagitis | Phase 3 | Completed | Celgene | 430 | 2021-02-22 | 2025-03-13 |
| A Study of Benralizumab in Patients With Eosinophilic Esophagitis Benralizumab, Matching placebo - Eosinophilic Esophagitis | Phase 3 | Terminated | AstraZeneca | 211 | 2020-09-22 | 2023-11-18 |
| Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) Dupilumab, Matching Placebo - Eosinophilic Esophagitis (EoE) | Phase 3 | Completed | Regeneron Pharmaceuticals | 102 | 2020-09-01 | 2025-10-27 |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Placebo, lirentelimab (AK002) - Eosinophilic Esophagitis | Phase 2 / Phase 3 | Completed | Allakos Inc. | 277 | 2020-07-06 | 2024-01-02 |
| A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab (AK002), Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 181 | 2020-06-18 | 2024-01-02 |
| Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 143 | 2020-01-30 | 2023-06-12 |
| Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Dupilumab, Placebo - Eosinophilic Esophagitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 321 | 2018-09-24 | 2023-06-28 |
| Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) Budesonide oral suspension - Eosinophilic Esophagitis (EoE) | Phase 3 | Terminated | Shire | 133 | 2017-10-05 | 2025-02-19 |
| SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study 1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure) - Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE) | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 129 | 2016-05-20 | 2020-05-26 |
| An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Oral Budesonide Suspension (OBS), Placebo - Eosinophilic Esophagitis (EoE) | Phase 3 | Completed | Shire | 219 | 2016-04-01 | 2025-02-19 |
| Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids 1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure) - Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs) | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 67 | 2016-03-21 | 2018-08-27 |
| Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Budesonide 0.5mg orodispersible tablet twice daily, Budesonide 1mg orodispersible tablet twice daily, Placebo orodispersible tablet twice daily - Eosinophilic Esophagitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 204 | 2016-01-15 | 2021-10-07 |
Showing 20 of 28. Sign in to see all of them.
Eosinophilia (6) · Esophageal Diseases (6) · Esophagitis (6) · Gastroenteritis (5) · Gastrointestinal Diseases (5) · Hypersensitivity (5) · Hematologic Diseases (4) · Leukocyte Disorders (4) · Eosinophilic enteropathy (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Digestive System Diseases (2) · Gastroesophageal Reflux (2) · Deglutition Disorders (1)
Hemic and Lymphatic Diseases (28) · Digestive System Diseases (26) · Hypersensitivity, Immediate (25) · Immune System Diseases (25) · Hematologic Diseases (24) · Leukocyte Disorders (24) · Gastroenteritis (23) · Gastrointestinal Diseases (23) · Hypersensitivity (23) · Eosinophilia (22) · Esophageal Diseases (22) · Esophagitis (22) · Deglutition Disorders (2) · Esophageal Motility Disorders (2) · Disease (1)
Fluticasone (6) · AK002 (4) · Budesonide (4) · APT-1011 (3) · dupilumab (3) · Endoscopy, Digestive System (2) · benralizumab (2) · cendakimab (2) · reslizumab (2) · BID protein, human (1) · Esomeprazole (1) · Sodium Chloride (1) · montelukast (1) · tezepelumab (1)
Allakos Inc. (4) · Dr. Falk Pharma GmbH (3) · Ellodi Pharmaceuticals, LP (3) · Regeneron Pharmaceuticals (3) · Shire (3) · AstraZeneca (2) · Celgene (2) · Ception Therapeutics (2) · Children's Hospital Medical Center, Cincinnati (2) · Marc Rothenberg (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (26) · Canada (9) · Australia (7) · Germany (7) · Spain (7) · Italy (5) · United Kingdom (5) · Belgium (4) · Israel (4) · Japan (4) · Netherlands (4) · Austria (3) · Poland (3) · Switzerland (3) · Argentina (2)
Craig Paterson, MD (4) · Evan Dellon, MD, MPH (2) · Marc E Rothenberg, MD, PhD (2) · Ralph Mueller, PhD (2) · Alfredo J Lucendo, MD, PhD (1) · Amy D Klion, M.D. (1) · Amy Foxx-Orenstein, D.O. (1) · Marc E. Rothenberg, M.D., Ph.D. (1) · Marc E. Rothenberg, MD, PhD (1) · Mirna Chehade, MD, MPH (1) · Nikhil Shastri, MD (1)
PMID 34182150, PMID 39735351, PMID 41749054, PMID 42031097, PMID 22111863, PMID 22206777, PMID 30922997, PMID 32721437, PMID 33887475, PMID 35283330, PMID 36546624, PMID 36863390, PMID 37660704, PMID 37718471, PMID 38010430, PMID 38050037, PMID 38924731, PMID 38924732, PMID 38940435, PMID 39384067, PMID 39631042, PMID 39694205, PMID 39777591, PMID 39909733, PMID 39954913, PMID 40120806, PMID 40985784, PMID 41534558, PMID 41711386, PMID 42093592, PMID 42658181, PMID 42836357
2014 (2), 2019 (2), 2018 (1), U54AI117804 (1)